ECOR - NASDAQ
electroCore, Inc.
$9.94
+0.81%electroCore, Inc., a commercial stage medical device company, engages in the development and commercialization of a range of non-invasive vagus nerve stimulation (nVNS) therapies. The company is developing gammaCore, a prescription-only nVNS therapy for the acute treatment of pain associated with migraine and episodic cluster headache in adults. Its lead product is gammaCore Sapphire, a rechargeable and reloadable handheld device for regular or intermittent use over many years. The company was incorporated in 2005 and is headquartered in Rockaway, New Jersey.
At a Glance
Live Snapshotecor
Effect of Foreign Exchange Changes on Cash
Last Annual Value
18.00K
3-Year CAGR
30%
5-Year CAGR
16%
10-Year CAGR
-8%
electroCore, Inc. Competitors Analysis of Effect of Foreign Exchange Changes on Cash
| Company | Effect of Foreign Exchange Changes on Cash | CAGR 3Y | CAGR 5Y | CAGR 10Y | |
|---|---|---|---|---|---|
electroCore, Inc. NASDAQ:ECOR | 18.00K | 44.2% | -36.5% | -8.4% | |
 MAIA Biotechnology, Inc. AMEX:MAIA | -5.22K | N/A | N/A | N/A |
electroCore, Inc. Fair Value Envelope
Related Guides
Continue your ECOR research with focused valuation guides.
Research Paths
Snapshot
Start with context, operating signals, and key market metrics.
Value Model
Stress test fair value across bear, base, and bull assumptions.
Statements
Validate revenue quality, margins, and balance sheet durability.
Earnings Call
Read management commentary and compare it with reported outcomes.
Dividends
Check payout sustainability and long-term distribution behavior.
Analyst Expectations
Review consensus spread and where estimate risk is concentrated.